Get to know our clinical trials
Clinical trial of Rilvegostomig in combination with chemotherapy as adjuvant treatment after biliary tract cancer resection with curative intent (ARTEMIDE-Biliary01)
THE AIM OF THE STUDY IS TO UNDERSTAND WHETHER THE TRIAL DRUG RILVEGOSTOMIG (ALONG WITH CHEMOTHERAPY) CAN HELP REDUCE THE RISK OF BILE DUCT CANCER COMING BACK AFTER SURGERY. ALSO TO BETTER UNDERSTAND BILIARY CANCER AND THE HEALTH PROBLEMS ASSOCIATED WITH IT.
Technical Summary
- INTERNATIONAL PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL OF RILVEGOSTOMIG IN COMBINATION WITH CHEMOTHERAPY AS ADJUVANT TREATMENT AFTER BILIARY TRACT CANCER RESECTION WITH CURATIVE INTENT (ARTEMIDE-BILIARY01)
- Code EudraCT: 2023-506054-20-00
- Protocol number: D7025C00001
- Promoter: Astra Zeneca AB
- Molecule/Drug: Rilvegostomig (AZD2936)
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.